Seo Y. Lee
Yangsan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
MHY5535, a novel PPARα antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 19, 2026
Role of Peroxisome Proliferator-Activated Receptor α-Dependent Mitochondrial Metabolism in Ovarian Cancer Stem Cells.
Journal: International journal of molecular sciences
Published: September 28, 2024
Identification of CD109 in the extracellular vesicles derived from ovarian cancer stem-like cells.
Journal: BMB reports
Published: January 15, 2024
BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
Journal: Anticancer research
Published: September 22, 2023
CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Journal: International journal of molecular sciences
Published: March 28, 2023
Kap1 Regulates the Stability of Lin28A in Embryonic Stem Cells.
Journal: Stem cells (Dayton, Ohio)
Published: July 30, 2021
TRIB2 Stimulates Cancer Stem-Like Properties through Activating the AKT-GSK3β-β-Catenin Signaling Axis.
Journal: Molecules and cells
Published: February 03, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026